Leerink Partnrs Brokers Lift Earnings Estimates for REGN

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Investment analysts at Leerink Partnrs increased their Q4 2024 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a report released on Tuesday, January 28th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will earn $9.82 per share for the quarter, up from their previous forecast of $8.81. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $37.73 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q1 2025 earnings at $6.80 EPS and FY2025 earnings at $33.55 EPS.

REGN has been the topic of several other reports. Barclays lowered their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Finally, Evercore ISI dropped their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,004.57.

Regeneron Pharmaceuticals Trading Down 0.6 %

NASDAQ:REGN opened at $683.08 on Thursday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a twelve month low of $666.25 and a twelve month high of $1,211.20. The company has a market cap of $75.06 billion, a P/E ratio of 16.90, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The business has a 50 day moving average price of $723.36 and a two-hundred day moving average price of $928.61.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Allworth Financial LP raised its position in shares of Regeneron Pharmaceuticals by 35.1% in the fourth quarter. Allworth Financial LP now owns 958 shares of the biopharmaceutical company’s stock valued at $651,000 after buying an additional 249 shares in the last quarter. Principal Securities Inc. increased its stake in Regeneron Pharmaceuticals by 43.9% during the 4th quarter. Principal Securities Inc. now owns 898 shares of the biopharmaceutical company’s stock worth $640,000 after acquiring an additional 274 shares during the period. Manchester Capital Management LLC raised its holdings in Regeneron Pharmaceuticals by 12.6% in the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 18 shares in the last quarter. ABC Arbitrage SA bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $1,510,000. Finally, Klingenstein Fields & Co. LP grew its holdings in shares of Regeneron Pharmaceuticals by 1,083.7% during the 4th quarter. Klingenstein Fields & Co. LP now owns 6,806 shares of the biopharmaceutical company’s stock worth $4,848,000 after purchasing an additional 6,231 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.